

CURRICULUM VITAE

Marc I. Lorber, M.D.

PRESENT TITLE: Professor of Surgery
Chief, Section of Organ Transplantation and Immunology,
Department of Surgery, Yale University School of Medicine
Director, Organ Transplantation, Yale-New Haven Hospital

ADDRESS: 333 Cedar Street, New Haven, CT 06520

Telephone: (203) 785-2565

EDUCATION: University of Illinois, Urbana-Champaign, IL
Bachelor of Science (with High Honors in Liberal Arts and Sciences
with High Distinction in General Biology; (6/73)

Rush Medical College, Chicago, Illinois
Doctor of Medicine, (6/77)

POSTGRADUATE: INTERNSHIP in Surgery, University of Michigan
Medical Center, Ann Arbor, Michigan (1977-78)

RESIDENCY in General Surgery and Transplantation,
University of Michigan Medical Center,
Ann Arbor, Michigan (1978-80) (1982-84)

Postdoctoral Research Fellowship in Immunobiology,
Department of Pathology, University of Chicago
Chicago, Illinois (Laboratory Director:
Frank W. Fitch, M.D., PhD: 1980-82)

Fellowship in Clinical Transplantation,
Department of Surgery, The University of Texas Health
Science Center at Houston, Texas (1984)

UNIVERSITY APPOINTMENTS:

Professor of Surgery 1993-
Chief, Section of Organ Transplantation and Immunology
Director, Histocompatibility and Immune Evaluation Laboratory
Department of Surgery, Yale University School of Medicine,
New Haven, Connecticut

Director, Yale Interdisciplinary Program in Clinical Transplantation 2000-

Associate Professor of Surgery 1987-93
Director, Division of Organ Transplantation and Immunology
Director, Histocompatibility and Immune Evaluation Laboratory
Department of Surgery, Yale University School of Medicine

Assistant Professor of Surgery Director, Division of Organ Transplantation and Immunology Director, Histocompatibility and Immune Evaluation Laboratory Department of Surgery, Yale University School of Medicine	1986-87
Assistant Professor, Department of Surgery, Division of Immunology and Organ Transplantation, The University of Texas Medical School at Houston, Texas.	1984-1986
<u>UNIVERSITY COMMITTEES :</u>	
Steering Committee, Cambridge-Yale Collaborative Research Program	2001 -
Steering Committee, Yale Interdepartmental Program in Vascular Biology and Transplantation Research	2000 -
Yale Medical Group; Electronic Medical Record Committee	2002 -
Senior Faculty Tenure Allotment Committee, Yale School of Medicine	1999- 2002
Yale Clinical Practice Group; Contracting Committee	2000 - 2002
Yale Clinical Practice Group; Finance Committee	1998- 2000
Department of Surgery; Appointments and Promotions Committee	1995
Department of Surgery, Executive Committee	1993-
Board of Permanent Officers; Yale University School of Medicine	1993-
Organ Transplantation Medical Review Board	1986-
Faculty Liaison; Committee on the Well Being of Students.	1992-94
Organizing Committee; Schell Center Program Human Rights and Organ Transplantation- An International Perspective. Yale University School of Medicine & Yale University Law School.	1991-93
Yale University School of Medicine, Department of Surgery, Surgery Education Committee	2002-
Yale University School of Medicine, Department of Surgery, Residency Coordinating Committee	1987-90
Yale University School of Medicine, Search Committee for Chief of Urology.	1987-88
<u>HOSPITAL APPOINTMENTS:</u>	
Yale-New Haven Hospital Attending Staff Chief of Organ Transplantation	1986-Present 1986-Present
Hermann Hospital, Houston, Texas; Active Staff	1984-86
St. Luke's Episcopal Hospital, Houston, Texas;	1985-86
<u>HOSPITAL COMMITTEES :</u>	
Yale-New Haven Hospital Xenotransplantation Committee	1996-
Yale-New Haven Hospital Surgery Departmental Committee.	1986-90, 93-
Yale-New Haven Hospital; Quality Assurance Committee.	1992-
Yale-New Haven Hospital; Surgery Reappointments Committee.	1990-91, 93-
Yale-New Haven Hospital Operating Room Committee.	1986-91
President's Cabinet, Yale-New Haven Hospital Medical Staff.	1989-92

NATIONAL AND REGIONAL SERVICE:

United Network for Organ Sharing (UNOS)

Secretary	2002- 2004
Board of Directors	1998 – 2000
Councilor, Region I	1998 - 2000
Renal Transplant Modeling Committee	1995 – 2000
Institutional Representative.	1987- Pres.
Associate Councilor, Region I	1996-1998
Membership & Professional Standards Committee	1994-98
Vice Chair	1996-98
Chair; Kidney-Pancreas Transplantation Committee	1994-96
Allocation Advisory Committee	1994-96
Vice Chair; Organ Procurement & Distribution Committee	1992-94
Scientific Advisory Committee	1988-90, 1992-94
Professional Education Committee	1987-88
Professional Education Committee (Ad Hoc Member)	1988-89
New England Organ Bank	
Board of Trustees.	1986-
Member of the Corporation	1987-
Executive Committee	1987-90; 93-93; 96-
Vice Chairman, Board of Trustees	1999- 2002
Nominating Committee.	1987
Chairman, Nominating Committee	1990
Search Committee for Executive Director	1988-89
Finance Committee	1988-89
Internal Review Steering Committee	1988-89
Chairman, Search Committee for Medical Director	1988-89
Columbus House Capital Campaign Physicians Committee	2002-
Yale-New Haven IPA Contracting Committee	1999-
New England End Stage Renal Disease Network	1987-94
Medical Review Board.	
Transplantation Advisory Committee,	1986-1992
State of Connecticut, Dept. Income Maintenance (ex officio).	
Solid Organ Transplantation Committee	1991-1997
Blue Cross/Blue Shield of Connecticut.	

RESEARCH STUDY SECTION/ REVIEW:

Department of Veterans Affairs	
Merit Review Board for Surgery (Ad hoc)	1992
Member, Merit Review Board for Surgery	1997 - 2000
National Institutes for Health	1992, 1994
Special Reviewer, SAT Study Section.	

PROFESSIONAL ORGANIZATIONS:

American Surgical Association	2000 -
American Society of Transplant Surgeons	1986 -
President, ASTS Foundation	2002 – 2003
President	2001 - 2002
President- Elect	2000 - 2001
Joint Executive Council, ASTS/ AST	1998-
Founding Committee, American Journal of Transplantation	1999 - 2000
Treasurer	1997 – 2000
Executive Council	1992 - 1995
Chairman, Program and Publications Committee	1989 - 1992
American Board of Surgery, Inc.	
Consultant, Qualifying Examination in General Surgery	1993 - 1998
American College of Surgeons, Fellow	1988 -
Board of Governors	1989 - 1992
Area Chairman, Committee on Development	1992 - 1996
American Society for Histocompatibility and Immunogenetics	1991 -
American Association for Study of Liver Diseases	1989 -
American Society of Transplant Physicians	1987 -
American Association of Immunologists	1986 -
American Association for the Advancement of Science	1985 -
Association for Academic Surgery	1984 -
Program Committee	1986 - 1988
Executive Council	1989 - 1992
Chicago Association of Immunologists	1980 - 1982
The Frederick A. Collier Surgical Society	1987 -
Executive Council	1995 - 1998
The Transplantation Society	1985 -
The Society of University Surgeons	1989 -
Committee on Social and Legislative Issues	1990 - 1993
Harris County Medical Society	1985 – 1986
Texas Medical Association	1984 - 1986
Yale Surgical Society	1996 -

LICENSURE (Active):

State of Connecticut 027545

CERTIFICATION:

National Board of Medical Examiners	1978
American Board of Surgery	1985
Re- certification	1995

HONORS:

Phi Eta Sigma Honor Society, University of Illinois,	1970
Honors Day Recognition, University of Illinois,	1970 - 73
Edmund J. James Scholar, University of Illinois,	1970 - 73
Phi Kappa Phi Honor Society, University of Illinois,	1971
Phi Beta Kappa Honor Society, University of Illinois,	1972
Alpha Omega Alpha Medical Honor Society, Rush Medical College,	1976

American Cancer Society Postdoctoral Fellowship PF-20-49,	1981 - 82
Maude T. Lane Scientific Research Award,	1982 - 84
American College of Surgeons Scholarship,	1981 - 83
Frederick A. Collier Travel Award,	1984
UTMSH Biomedical Research Support Grant, (relinquished 9/86 with move to Yale)	1985 - 87
Fellowship, Branford College, Yale University	1991
Master of Arts Degree (Honorary), Yale University	1993
International Advisory Committee, Fourth International Congress on Cyclosporine	1995

JOURNAL REVIEW, EDITORIAL POSITIONS :

Transplantation	1987-
Journal of Surgical Research	1986-
Transplantation Proceedings	1985-
Immunopharmacology	1988 - 1990
Journal of Immunology	1987, 1991
Journal of Biochemical Pharmacology	1987
Journal of Clinical Investigation	1994
Human Immunology	1985

Journal Oversight Committee, American Journal of Transplantation
 Editorial Board, Transplantation
 Editorial Board, Transplantation Proceedings
 Editorial Board, Graft
 Editorial Board, Transplantation and Immunology Letter
 Editorial Board, Journal of Surgical Research
 Editorial Board, Transplantation Science
 Editor, Transplant Digest.

TRAINEES AND POSTDOCTORAL FELLOWS:

Debra A. Simone, RN, MS. Yale University School of Nursing Parental Attitudes Toward Organ Donation Masters Thesis .	1987 - 1989
Karamchand Paul, MD. Yale University School of Medicine Cyclophilin Binding as an Approach to Monitoring Cyclosporine Immunosuppression. Postdoctoral Associate.	1988 - 1990
Eric A. Richard. Yale University School of Medicine Medical School Thesis Advisor Infectious Complications Following OKT-3 Therapy.	1989 - 1991
Monica McDonald. Yale University School of Medicine Medical School Thesis Advisor	1988 - 1991.

Cyclophilin Tissue Content: An Ultrastructural Analysis.	
Kenneth Vives. Yale University School of Medicine Medical School Thesis Advisor Nuclear Membrane Associated FK-506 Binding Proteins.	1991 - 1993
Dr. Ivan Darenkov The Immunopathogenesis of Chronic Allograft Rejection Yale University School of Medicine Post Doctoral Research Fellow	1995 – 1998
Dr. Ravi Kumar Allogeneic Arterial Injury in the hu/SCID Mouse Yale University School of Medicine Post Doctoral Research Fellow	1998 - 1999
Dr. Tamara Toidze Allogeneic Arterial Injury Yale University School of Medicine Post Doctoral Research Fellow	1999- 2000
Dr. Tai Yi Alloimmune Arterial Injury Yale University School of Medicine Post Doctoral Research Fellow	2001- Pres.
Lixin Zhang Yale University School of Medicine Post Doctoral Research Fellow	2002 – Pres.

RECENT RESEARCH FUNDING:

An Open Label, concentration controlled, randomized, 12 month study of tacrolimus, sirolimus and corticosteroids vs. cyclosporine, sirolimus & corticosteroids in high risk renal allograft recipients.

Role in Project: Principal Investigator
Sponsor: Wyeth-Ayerst Pharmaceuticals

A randomized, open label, comparative evaluation of conversion from calcineurin inhibitors to sirolimus, vs. continued use of calcineurin inhibitors in renal allograft recipients

Role in Project: Principal Investigator
Sponsor: Wyeth-Ayerst Research

A 1 Year Multicenter, Randomized, open label, parallel group study of the safety, tolerability and efficacy of doses (1.5 And 3 Mg/Day) of Everolimus (Certican™; Rad001) with Basiliximab (Simulect®), Corticosteroids and Optimized Administration of Cyclosporine (Neoral®) in *de novo* Renal Transplant Recipients

Role in Project: Principal Investigator
Sponsor: Novartis Pharmaceuticals

A one-year, multicenter, prospective, open-label study of the safety, tolerability, and preliminary efficacy of oral FTY20 and RAD001 in *de novo* adult renal transplant recipients at increased risk of delayed graft function

Role in Project: Principal Investigator
Sponsor: Novartis Pharmaceuticals Corporation

A phase I/II, open label, multicenter, multiple dose study to evaluate the safety, pharmacokinetics/pharmacodynamics and biological activity of subcutaneously administered anti-CD11a (hu1124) in patients receiving a primary renal transplant

Role in Project: Principal Investigator

Sponsor: Xoma Pharmaceuticals

A Phase I Randomized, Third-Party Unblinded, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Doses of Humanized Anti-B7.1 (h1F1) and Anti-B7.2 (h3D1) Antibodies in De Novo Renal Allograft Recipients

Role in Project: Principal Investigator

Sponsor: Genetics Institute Corporation

A Three Year, Randomized, Multicenter, Double-Blind, Parallel Group Study of the Efficacy and Safety of SDZ RAD Tablets Versus Mycophenolate Mofetil as Part of Triple Immunosuppressive Therapy in De Novo Renal Transplant Recipients (RADB 251)

Role in Project: Principal Investigator

Sponsor: Novartis Pharmaceuticals Corporation

An open label study to evaluate the safety of steroid withdrawal in de novo renal allograft recipients treated with basiliximab induction and tacrolimus in combination with sirolimus (RAPA 505).

Role in Project: Principal Investigator

Sponsor: Wyeth-Ayerst Research

Human CTL Mediated Injury of Graft Endothelial Cells

Sponsor: NIH RO1 (HL 62188)

Role in Project: Co-Investigator; PI – Jordan Pober

Chronic DTH and IFN γ in Human Graft Arteriosclerosis

Role in Project; Co- Project Leader; PI – Jordan Pober

Sponsor: NIH PO-1

Pending/ in Preparation:

Transimmunization for Establishing Immune Tolerance after Renal Transplantation

Role in Project: Principal Investigator

Sponsor: The Immune Tolerance Network

Projected Date: July, 2003

Immunopathogenesis of Human Vascular Rejection

Role in Project: Principal Investigator

Sponsor: NIH RO-1

Projected Date: July, 2003

BIBLIOGRAPHY:

A. ARTICLES IN JOURNALS:

1. Silver, TM, Campbell, DA, Jr., Wicks, JD, **Lorber MI**, Surance, P and Turcotte, JG. Peritransplant fluid collections: Ultrasonic evaluation and clinical significance. Radiology. 138:145-151, 1981.

2. Brain, J, **Lorber MI**, and Fiddian-Green, RG. Rectal membrane as an unusual complication following circular stapling in colorectal anastomosis. *Surgery*. 89: 271-274, 1981.
3. Campbell, DA, Jr., **Lorber MI**, Arneson, WA, Kirsh, MM, Turcotte, JG and Stanley, JC. Renal transplant protection during abdominal aortic aneurysmectomy using a pump oxygenator. *Surgery*. 90:559-562, 1981.
4. **Lorber MI**, Campbell, DA Jr., Konnak, JW, Silver, TM, and Turcotte, JG. Etiology and management of early and late peritransplant fluid collections. *J. Urol*. 127:870-872, 1982.
5. **Lorber MI**, Loken, MR, Stall, AM, and Fitch, FW. I-A antigens on cloned alloreactive murine T lymphocytes are acquired passively. *J. Immunol*. 128: 2798-2803, 1982.
6. Sarmiento, M, Dialynas, DP, Lancki, DW, Wall, KW, **Lorber MI**, Loken, MR, and Fitch, FW. Cloned T lymphocytes and monoclonal antibodies as probes for cell surface molecules active in T cell mediated cytotoxicity. *Immunol. Rev*. 68:135-169, 1982.
7. Campbell, DA, Jr., **Lorber MI**, Sweeton, JC, Turcotte, JG, and Beer, AE. Breast feeding and maternal donor related renal allografts: Influence of breast feeding on reactivity to the allograft. *Transplant. Proc*. 15:906-909, 1983.
8. Lancki, DW, **Lorber MI**, Loken, MR and Fitch, FW. A clone specific monoclonal antibody which inhibits cytotoxicity of a cytotoxic T cell clone. *J. Exp. Med*. 157: 921-935, 1983.
9. Wall, KA, **Lorber MI** and Fitch, FW. Inhibition of proliferation of M1s and Ia reactive cloned T cells by a monoclonal antibody against a determinant shared by I-A and I-E. *J. Immunol*. 131: 1056-1064, 1983.
10. **Lorber MI**, Dawson, PJ, Loken, MR, Ely, JM, Fieldsteel, AH, and Fitch, FW. T cell lineage of a virus-induced lymphatic leukemia in athymic rats. *J. Natl. Cancer Inst*. 71: 1271-1280, 1983.
11. Kois, WE, Campbell, DA, **Lorber MI**, Sweeton JC and Dafoe, DC. Influence of breast feeding on subsequent reactivity to a related renal allograft. *J. Surg.Res*. 37: 89-93, 1984.
12. **Lorber MI**, Wall, KA, Loken, MR, and Fitch, FW. Control of cloned alloreactive T lymphocyte proliferative responses: A possible role for cell surface bound alloantigen. *Transplantation*. 38: 361-370, 1984.
13. Campbell, DA, **Lorber MI**, Sweeton, JC, Turcotte, JG, Niederhuber, JE and Beer, AE. Breast feeding and maternal-donor related renal allografts: Possibly the original donor-specific transfusion? *Transplantation*. 37:340-344, 1984.
14. Flechner, SM, **Lorber MI**, Van Buren, CT, Kerman, RH, and Kahan, BD. The case against conversion to azathioprine in cyclosporine-treated renal transplant recipients. *Transplant. Proc*. 17:276-281, 1985.

15. Kahan, BD, Van Buren, CT, **Lorber MI**, Flechner, SM, Wideman, CA and Kerman, RH. Optimization of cyclosporine immunosuppression for renal transplantation. *Transplant. Proc.* 17:35-43, 1985.
16. **Lorber MI**, Flechner, SM, Van Buren, CT, Kerman, RH and Kahan, BD. Cyclosporine, azathioprine, and prednisone as treatment for cyclosporine induced nephrotoxicity in renal transplant recipients. *Transplant. Proc.* 17:282-285, 1985.
17. Kerman, RH, Flechner, SM, Van Buren, CT, **Lorber MI**, and Kahan, BD. Successful transplantation of cyclosporine treated allograft recipients with serologically positive historical, but negative preoperative donor crossmatches. *Transplantation.* 40: 615-629, 1985.
18. Flechner, SM, **Lorber MI**, Kerman, RH, Van Buren, CT, Wideman, C, and Kahan, BD. Does cyclosporine influence the results of cadaver retransplantation? *Hu. Immunol.* 14:305-313, 1985.
19. Kerman, RH, Van Buren, CT, Flechner, SM, **Lorber MI**, and Kahan, BD. The beneficial effect of cyclosporine on renal transplantation at a single U.S. transplant center. *Transplant. Proc.* 17:2193-2195, 1985.
20. Flechner, SM, Sandler, CM, Houston, GK, Van Buren, CT, **Lorber MI**, and Kahan, BD. 100 Living related kidney donor evaluations using digital subtraction angiography. *Transplantation.* 40:675-678, 1985.
21. Kahan, BD, **Lorber MI**, Flechner, SM, Van Buren, CT, Jensen, C and Wideman, CA. Comparison of five cyclosporine-prednisone regimens for induction of immunosuppression in cadaveric kidney recipients: a retrospective analysis of 245 cases. *Transplant. Proc.* 18 (Suppl. 1): 59-65, 1986.
22. Kahan, BD, Kramer, WB, Wideman, C, Flechner, SM, **Lorber MI**, and Van Buren, CT. Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay. *Transplantation* 41: 459-565, 1986.
23. Kahan, BD, Flechner, SM, **Lorber MI**, Jensen, C, Golden, D and Van Buren, CT. Complications of cyclosporine therapy. *World J. Surg.* 10: 348-360, 1986.
24. Flechner, SM, Van Buren, CT, Kerman, RH, **Lorber MI**, Barker, CJ, Golden, DL and Kahan, BD. Long term results of cyclosporine therapy in recipients of mismatched living related kidneys. *Transplant. Proc.* 18 (Suppl. 1):44-49, 1986.
25. Kahan, BD, Kerman, RH, Flechner, SM, **Lorber MI**, and Van Buren, CT. Impact of Sandimmune on renal transplant results, the University of Texas Medical School, Houston. *Proc. Second Asian Workshop on Cyclosporine.* Excerpta Medica Asia. 17-22, 1986.
26. Jarowenko, MV, Van Buren, CT, Kramer, WG, **Lorber MI**, Flechner, SM and Kahan, BD. Ranitidine, cimetidine and the cyclosporine treated recipient. *Transplantation.* 42:311-312, 1986.
27. Kahan, BD, Kerman, RH, Flechner, SM, **Lorber MI**, and Van Buren, CT. Clinical Results of Cyclosporine-Prednisone Therapy. *Contrib. Nephrol.*;51:55-60, 1986.

28. Kahan, BD, Kramer, WG, Wideman, CA, Frazier, OH, **Lorber MI**, Williams, C, Flechner, SM, Cooley, DA, Van Buren, CT. Analysis of pharmacokinetic profiles in 232 renal and 87 cardiac allograft recipients treated with cyclosporine. *Transplant. Proc.* 18 (Suppl. 5):115-119, 1986.
29. Kerman, RH, Van Buren, CT, Flechner, SM, **Lorber MI**, and Kahan, BD. Successful renal allograft survival for CsA-treated recipients displaying positive historical donor cross matches. *Transplant. Proc.* 18:680-682, 1986.
30. Kahan, BD, Flechner, SM, **Lorber MI**, and Van Buren, CT. Management of chronic Cyclosporine Related Nephrotoxicity. *Contrib. Nephrol.* 51: 96-101, 1986.
31. Jensen, CWB, Flechner, SM, Van Buren, CT, Frazier OH, Cooley, DA, **Lorber MI**, and Kahan, BD. Exacerbation of cyclosporine toxicity by concomitant administration of erythromycin. *Transplantation.* 43: 263-270, 1987.
32. Dafoe, DC, Stoolman, LM, Campbell, DA, **Lorber MI**, Waskerwitz, J, Turcotte, JG: T cell subset patterns in cyclosporine treated renal transplant recipients with primary CMV disease. *Transplantation.* 43: 452-454, 1987.
33. Burstain, TL, Frazier, OH, Schnee, MJ, Kerman, RH, **Lorber MI**, Cooley, DA, Radovancevic, B, Colon, R, McAllister, H, Kahan, BD, Van Buren, CT. Predictors of rejection in cyclosporine treated cardiac allograft recipients. *Transpl. Proc.* 19: 2531-2533, 1987.
34. **Lorber MI**, Van Buren, CT, Flechner, SM, Williams, C, Kahan, BD. Hepatobiliary complications of cyclosporine following renal transplantation. *Transpl. Proc.* 19: 1809-1810, 1987.
35. **Lorber MI**, Van Buren, CT, Flechner, SM, Cameron, L, Leatherwood, J, Walker, WE, Smalling, RW, Kahan, BD. Pretransplant coronary arteriography for diabetic renal transplant recipients. *Transpl. Proc.* 19: 1539-1541, 1987.
36. Flechner, SM, Kerman, RH, VanBuren, CT, **Lorber MI**, Barker, C, Kahan, BD. Does CsA improve results of HLA-ident. renal transplantation? *Transpl. Proc.* 19:1485-1588, 1987.
37. Kerman, RH, Flechner, SM, Van Buren, CT, **Lorber MI**, Dawson, G, Falk, L, Gutierrez, R, Hollinger, JB, and Kahan, BD. Investigation of HTLV-3 serology in a renal transplant population. *Transpl. Proc.* 19: 2172-2175, 1987.
38. Kerman, RH, Flechner, SM, Van Buren, CT, **Lorber MI**, Kahan, BD. Role of suppressor cells in cyclosporine treated allograft recipients. *Transpl. Proc.* 19: 1580-1583, 1987.
39. **Lorber MI**, Flechner, SM, Van Buren, CT, Sorenson, K, Kerman, RH, and Kahan, BD. Management of immunosuppressive problems in renal allograft recipients. *Transpl. Proc.* 19:1951-1954, 1987.
40. Jarowenko, MV, Flechner, SM, Van Buren, CT, **Lorber MI**, Kahan, BD. Influence of cyclosporine on posttransplant blood pressure response. *Am. J. Kidney Dis.* 10: 98-103, 1987.

41. Kahan, BD, Mickey, R, Flechner, SM, **Lorber MI**, Wideman, CA, Kerman, RH, Terasaki, P, Van Buren, CT. Risk factors for cadaveric donor allograft survival in cyclosporine-prednisone treated recipients. *Transpl. Proc.* 19:1835-1838, 1987.
42. Kerman, RH, Flechner, SM, Van Buren, CT, **Lorber MI**, Dawson, G, Falk, L, Gutierrez, R, Hollinger, JB, Kahan, BD. Investigation of HTLV-3 serology in a renal transplant population. *Transplantation.* 43: 244-248, 1987.
43. Kahan, BD, Flechner, SM, **Lorber MI**, Golden, D, Conley, S, Van Buren, CT. Complications of cyclosporine-prednisone immunosuppression in 402 renal allograft recipients exclusively followed at a single center for 1 to 5 years. *Transplantation.* 43: 197-204, 1987.
44. **Lorber MI**, Van Buren, CT, Flechner, SM, Williams, C, Kahan, BD. Hepatobiliary and pancreatic complications of cyclosporine therapy in 466 renal transplant recipients. *Transplantation.* 43: 35-40, 1987.
45. Kahan, BD, Mickey, R, Flechner, SM, **Lorber MI**, Wideman, CA, Kerman, RH, Terasaki, P, Van Buren, CT. Multivariate analysis of risk factors impacting on immediate and eventual cadaver allograft survival in cyclosporine treated recipients. *Transplantation.* 43:65-70, 1987.
46. **Lorber MI**, Flechner, SM, Van Buren, CT, Sorensen, K, Kerman, RH, Kahan, BD. Cyclosporine Toxicity: the effect of combined therapy using cyclosporine, azathioprine, and prednisone. *Am. J. Kid. Dis.* 9: 476-584, 1987.
47. Kerman, RH, Flechner, SM, Van Buren, CT, **Lorber MI**, Kahan, BD. Immuno-regulatory mechanisms in cyclosporine treated renal allograft recipients. *Transplantation.* 43:205-210, 1987.
48. Colon, R, Frazier, OH, Kahan, BD, Radovancevic, B, Duncan, JM, **Lorber MI**, Van Buren, CT. Complications in cardiac transplant patients requiring general surgery. *Surgery.* 103: 32-38, 1987.
49. Warshauer, DM, Taylor, KJW, Bia, MJ, Marks, WH, Weltin, GG, Rigsby, CM, True, LD, **Lorber MI**. Duplex Doppler evaluation of the renal transplant: Unusual causes of increased vascular impedance in renal transplants: Duplex Doppler Evaluation, *Radiology.* 169: 367-370; 1988.
50. Vasseur, B, Marks, WH, **Lorber MI**, Taylor, K. Renal Allograft Rejection: Pitfalls in Doppler Ultrasound Analysis. *Surgical Forum,* 39: 678-680, 1988.
51. Pachon, J, **Lorber MI**, Bia, MJ. Effects of H₂-Receptor antagonists on renal function in Cyclosporine treated renal transplant patients. *Transplantation.* 47:254-259. 1989.
52. Marks, WH, Borgstrom, A, Sollinger, H, Marks, C, **Lorber MI**. Serum anodal trypsinogen is a predictive biochemical marker for pancreas rejection. *Transpl. Proc.* 22: 673-675, 1990.
53. **Lorber MI**, Paul, K, Harding, MW, Handschumacher, RE, Marks, WH. Cyclophilin Binding; a receptor mediated approach to monitoring cyclosporine immunosuppressive activity following organ transplantation. *Transpl. Proc.* 22: 1240-1245. 1990.

54. Marks WH, Harding MW, Marks C and **Lorber MI**. Cyclophilin, the natural receptor for cyclosporine. In: Proceedings of the Norman R. Farnsworth Symposium on Natural Products Research, 1990.
55. Marks, WH, Borgstrom, A, Marks, CR, Sollinger, H, **Lorber MI**. Serum markers for pancreas rejection: long term behavior following clinical pancreatico-duodenal transplantaton. *Transpl. Proc.* 23: 1596-1597. 1991.
56. Paul, K, Harding, MW, Marks, WH, Handschumacher RE, **Lorber MI**. Cyclophilin binding: a more accurate measure of cyclosporine immunosuppressive activity after renal transplantation. *Transpl. Proc.* 23: 974-975. 1991.
57. Koneru, B, Flye, MW, Busuttil, RW, Shaw, BW, **Lorber MI**, Emond, JC, Kalayoglu, M, Freese, DK, Starzl, TE. Liver Transplantation for hepatoblastoma: The American Experience. *Annals of Surgery*, 213: 118-121. 1991.
58. **Lorber MI**, Wilson, JH, Harding, MW, Marks, WH. A comparison of in vivo response to cyclosporine, FK-506 and rapamycin following allogeneic immune challenge. *Transplantation*, 52: 167-170. 1991.
59. Marks, WH, Harding, MW, Handschumacher, RE, Marks, C, **Lorber MI**. The immunochemical distribution of cyclophilin in normal mammalian tissues. *Transplantation*. 52: 340-345, 1991.
60. Marks, WH, Perkal, MF, **Lorber MI**. Aseptic encephalitis and blindness complicating OKT3 Therapy. *Clin. Transplantation*. 5: 435-438. 1991.
61. SanFilippo, FP, Vaughn, WK, Peters, TG, Shield, CF III, Adams, PL, **Lorber MI**, Williams, GM. Factors affecting the waiting time of candidates for cadaver donor kidney transplantation in the United States. *JAMA*. 267: 247-252. 1992.
62. Perkal, MF, **Lorber MI**, Marks, WH. A 3 year clinical experience using serum anodal trypsinogen, a biochemical marker for rejection in pancreatic allografts: false positives, tissue biopsy, comparison to other markers & diagnostic strategies. *Transplantation*, 53:415-419. 1992.
63. McDonald, ML, Ardito, T, Marks, WH, Kashgarian, M, **Lorber MI**. The effect of cyclosporine therapy on the cellular distribution and content of cyclophilin. *Transplantation*. 53: 460-466. 1992.
64. Richard, E, **Lorber MI**, Marks, WH, Bia, MJ. Are calcium channel blockers protective against first dose reactions to OKT3. *Transplantation*. 54: 372-374. 1992.
65. Perkal, MF, Haber, MM, Nelson, K, Marks, WH, Reuben, A, West, AB, **Lorber MI**. Cytomegalovirus Appendicitis in a liver transplant recipient. *Clinical Transpl.* 6: 384-387. 1992.

66. Perkal, MF, Gulino, D, Delfini, RH, Siegel, NJ, Gaudio, K, Marks, WH, **Lorber MI**. Severe gingival overgrowth associated with cyclosporine and verapamil therapy. *Clinical Transpl.* 6: 399-402. 1992.
67. Azhderian, EM, Kolipaka, J, Lentz, S, **Lorber MI**. Nuclear associated cyclophilins of potential importance in cyclosporine immunosuppression. *Transpl. Proc.* 25: 524-526. 1993.
68. Azhderian, EM., Vives, K, **Lorber MI**. Nucleus associated FK506 binding proteins with potential relevance to FK506 immunosuppression. *Transpl. Proc.* 25: 662-664. 1993.
69. Powelson, JA, Cosimi, AB, RL, Lewis, WD, Rohrer, RJ, Freeman, RB, Vacanti, JP, Jonas, M, **Lorber MI**, Marks, WH, Bradley, J, Jenkins, RL. Hepatic retransplantation in New England: a regional experience and survival model. *Transplantation.* 55: 830-834. 1993.
70. Souba, WW, Gamelli, RL, **Lorber MI**, Thompson, JS, Kron, IL, Tomkins, RG, Hoyt, DB. Strategies for Success in Academic Surgery. *Surgery.* 117: 90 - 96. 1995.
71. Morrissey, PL, Lorber, KM, Marcarelli, M, Bia, MJ, Kliger, AS, **Lorber MI**. Post transplant Epstein Barr virus infection is associated with elevated levels of CD19⁺ B lymphocytes. *Transplantation.* 59: 637-640. 1995.
72. Perazella M, McPhedran P, Kliger A, **Lorber MI**, Levy E, Bia MJ. Enalapril treatment of posttransplant erythrocytosis: efficacy independent of circulating erythropoietin levels. *Am J. Kidney Dis.* 26: 495-500. 1995.
73. Pereira, B.J.G for the New England Organ Bank Hepatitis C Study Group. A controlled study of hepatitis C transmission by organ transplantation. *Lancet.* 325: 484-487. 1995
74. Morrissey, P.E., Lorber, K.M., Marcarelli, M, Bia, MJ, Kliger, AS, **Lorber MI**. Immunologic Monitoring after Organ Transplantation: Relationship between Epstein Barr Virus infection and CD19⁺ B Cells measured by flow cytometry. *Transpl. Proc.* 27: 1428-1430. 1995.
75. Auersvald LA, Perez RV, **Lorber MI**, Friedman AL, Bia MJ, Gruber J, Basadonna GP. Serum sialic acid, a risk factor for cardiovascular disease improves following pancreas transplantation. *Transpl. Proc.* 27: 3037. 1995.
76. Hibberd, PL, Tolkoff-Rubin, NE, Conti, D, Cosimi, AB, Stewart, F, Thistlethwaite, JR, Neylan, JF, Snyderman, DR, **Lorber MI**, Doran, M, Delvecchio, A, Rubin, RH. A controlled trial of preemptive ganciclovir for the prevention of symptomatic cytomegalovirus disease in cytomegalovirus seropositive renal transplant recipients receiving antilymphocyte antibody therapy. *Annals Internal Medicine.* 123: 18-26. 1995.
77. Washburn WK, Bradley J, Cosimi AB, Freeman RB, Hull D, Jenkins RL, Lewis WD, **Lorber MI**, Schweizer RT, Vacanti JP, Rohrer RJ. A regional experience with emergency liver transplantation. *Transplantation.* 61: 235-238. 1996.

78. Auersvald LA, Friedman AL, **Lorber MI**, Basadonna GP. Pancreas after kidney transplantation in type I Diabetic recipients high success rate is independent of poor HLA matching. *International Journal of Pancreatology*. 19: 211. 1996.
79. Chambers SK, Davis CA, Chambers JT, Schwartz, PE, **Lorber MI**, Handschumacher RE. Phase I trial of intravenous carboplatin and cyclosporine A in refractory gynecologic cancer patients. *Clinical Cancer Research*. 2:1699-1704. 1996.
80. **Lorber MI**, Basadonna GP, Friedman AL. Pathophysiology and treatment of gallstone disease in organ transplant recipients. *Journal of Nephrology*. 9: 225-231. 1996.
81. Friedman AL, Goker O, Dennis MJ, Basadonna GP, Wiklund RA, Kliger AS, Bia MJ, **Lorber MI**. Must living renal donors be hospitalized overnight prior to surgery. *Clin. Transplantation*. 10: 444-446. 1996.
82. Smith SD, Wheeler MA, Zhang R, Weiss ED, **Lorber MI**, Sessa WC, Weiss RM. Nitric oxide synthase induction with renal transplant rejection or infection. *Kidney Int*. 50:2088-2093. 1996.
83. Lee LS, Auersvald LA, Claus EB, Bia MJ, Friedman AL, **Lorber MI**, Basadonna, GP. Body size mismatch between donor and recipient and the development of chronic rejection in renal transplantation. *Transpl. Proc*. 29: 111. 1997.
84. Basadonna GP, Auersvald LA, Friedman AL, **Lorber MI**. Pancreas after kidney transplantation: HLA mismatch doesn't preclude success. *Transpl. Proc*. 29:667. 1997.
85. Kerman RH, Oroc, CG, **Lorber MI**. Clinical relevance of anti-HLA antibodies pre and post transplant. *Am. Journal Med Sciences*. 313: 275-278. 1997.
86. Sultan P, Schechner JS, McNiff JM, Hochman PS, Hughes CCW, **Lorber MI**, Askenase PW, Pober JS. Blockade of CD2-LFA3 Interactions Protects Human Skin Allografts in the huPBL-SCID Mouse. *Nature Biotechnology*. 15; 759-762. 1997.
87. Sultan P, Murray AG, McNiff JM, **Lorber MI**, Askenase PW, Bothwell ALM, Pober JS. Pig but not human interferon-G initiates human cell mediated rejection of pig tissue *in vivo*. *Proc. Natl. Acad. Sci. (USA)*. 94: 8767-8772. 1997.
88. Chambers SK, Chambers JT, Davis CA, Kohorn EI, Schwartz PE, **Lorber MI**, Handschumacher RE, Pizzorno G. Pharmacokinetic and phase I trial of intraperitoneal carboplatin and cyclosporin A in refractory ovarian cancer patients. *Journal of Clinical Oncology*. 15: 1945-1952. 1997.
89. Darenkov IA, Marcarelli MA, Basadonna GP, Friedman AL, Lorber KM, Howe JG, Crouch J, Bia MJ, Kliger AS, **Lorber MI**. Reduced incidence of Epstein- Barr Virus associated post transplant lymphoproliferative disorder using preemptive anti- viral therapy. *Transplantation*. 64: 848-852. 1997.
90. Olsson LE, Swana H, Friedman AL, **Lorber MI**. Pleurotomy, pneumothorax, and surveillance during living donor nephroureterectomy. *Urology*. 52(4): 591-3. 1998

91. Murray AG, Schechner J, Epperson DE, Sultan P, McNiff JM, Hughes CCW, **Lorber MI**, Askenase PW, Pober JS. Dermal Microvascular Injury in the Hu-PBL SCID Mouse Skin Allograft Model is T Cell Mediated and Inhibited by a Combination of Cyclosporine and Rapamycin. *Am J Pathol.* 153: 627-638. 1998.
92. Pober J, Schechner J, Murray A, Sultan P, Kirkiles N, Tereb D, Wilson J, McNif J, Askenase P, Tellides G, **Lorber MI**. Allogeneic and Xenogeneic Vascular Injury and Protection. *Transpl. Proc.* 30: 4168 - 4169. 1998.
93. Delmonico F, Harmon W, **Lorber MI**, Goguen J, Mah H, Himmelfarb J, Lipkowitz G, Valliere S, Milford E, Rohrer R. A new allocation plan for renal transplantation. *Transplantation.* 67: 303 – 308. 1999.
94. **Lorber MI**, Wilson JH, Robert ME, Schechner JS, Kirkiles N, Askenase PW, Tellides G, Pober JS. Human allogeneic vascular rejection after arterial transplantation and peripheral lymphoid reconstitution in SCID mice. *Transplantation.* 67: 897-903, 1999.
95. Delmonico F, Harmon W, **Lorber MI**, Goguen J, Mah H, Himmelfarb J, Lipkowitz G, Valliere S, Milford E, Rohrer R. A new allocation plan for renal transplantation. *Transpl. Proc.* 31: 358-360. 1999.
96. Delmonico FL, Milford EL, Goguen J, Harmon WE, Lipkowitz G, Himmelfarb J, Mah H, Rohrer RJ, **Lorber MI**. A novel UNOS region kidney allocation plan improves transplant access for minority candidates. *Transplantation.* 68: 1875-1879. 1999.
97. Tellides G, Tereb DA, Kirkiles NC, Kim RW, Schechner JS, **Lorber MI**, Pober JS. Interferon- γ directly elicits coronary arteriosclerosis *in vivo*. *Nature.* 403: 207-211. 1999.
98. Cayco A, Wysolmerski J, Simpson C, Mitnick MA, Gundreberg C, Kliger A, **Lorber MI**, Silver D, Basadonna G, Friedman, A, Insogna, K, Cruz, D, Bia, M. Post transplant bone disease: evidence for a high bone resorption state. *Transplantation.* 70: 1722-1728. 2000.
99. Smith SD, Wheeler MA, **Lorber MI**, Weiss RM. Temporal changes of cytokines and nitric oxide products in urine from renal transplant recipients. *Kidney Int.* 58:829-837. 2000.
100. **Lorber, MI**, Fastenau J, Wilson D, DiCesare J, ML Hall, for the US Simulect Study Group. A prospective economic evaluation of basiliximab (Simulect) therapy following renal transplantation. *Clinical Transplantation.* 14: 479- 485. 2000.
101. Kirkiles NC, Tereb DA, Kim RW, McNiff JM, Schechner JS, **Lorber MI**, Pober JS, Tellides G. Human TNF can induce nonspecific inflammatory & immune mediated microvascular injury of pig skin xenografts in immunodeficient mice. *J. Immunology.* 164:6601-6609. 2000.
102. Kahan BD, Rapamune US Study Group, **Lorber MI**. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre trial. *Lancet.* 356:194. 2000.

103. Schechner JS, Nath A, Zheng L, Kluger MS, Hughes CW, Sierra-Honigmann MDL, **Lorber MI**, Tellides G, Kashgarian M, Bothwell ALM, Pober JS. In vivo formation of complex micro- vessels lined by human endothelial cells in an immunodeficient mouse. Proc. National Acad. Sci (USA). 97: 9354-9356. 2000.
104. Cruz DN, Wysolmerski JJ, Brickel HM, Gundberg CG, Simpson CA, Mitnick MAE, Kliger AS, **Lorber MI**, Friedman AL, Basadonna GP, Insogna KL, Bia MJ. Parameters of high bone turnover predict bone loss in renal transplant patients. Transplantation. 72: 83-88. 2001.
105. Tereb, DA, Kirkiles-Smith NC, Kim RW, Rudic RD, Schechner JS, **Lorber MI**, Pober JS, Tellides G. Unsensitized human T cells do not infiltrate or injure quiescent pig coronary artery grafts in immunodeficient mouse hosts. Transpl. Proc. 33: 695. 2001.
106. Kirkiles-Smith, NC, Tereb DA, Schechner JS, McNiff JM, **Lorber MI**, Pober JS, Tellides G. Endothelial cell activation by tumor necrosis factor elicits human antiporine cell mediated rejection responses. Transpl. Proc. 33: 412. 2001.
107. Kovarik JM, Kahan BD, Lorber MI, Kaplan B, Winkler M, Rouilly M, Gerbeau C, Cambon N, Boger R, Rordorf C. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post transplant year: Pharmacokinetics, exposure- response relationships & influence on cyclosporine. Clin. Pharmacol. Therapeutics. 69: 48. 2001.
108. Tereb DA, Kirkiles-Smith, NC, Schechner JS, **Lorber MI**, M. Bothwell ALM, Pober JS, Tellides G. Human T cells infiltrate & injure pig coronary artery grafts with activated but not quiescent endothelium in immunodeficient mouse hosts. Transplantation. 71: 1622. 2001.
109. Glickman MM, Stokes GK, Schuman ED, Sternbergh WC III, Lindberg JS, Money SM, **Lorber MI**. Multicenter evaluation of Thoratec Vectra vascular access grafts as compared to ePTFE vascular access grafts in hemodialysis applications. J. Vasc. Surg. 34: 465-473. 2001.
110. **Lorber MI**, Basadonna GP, Friedman AL, Lorber KM, Bia MJ, Formica R, Smith JD. The evolving role of TOR inhibitors for individualizing post transplant immunosuppression. Transpl. Proc. 33: 3075-3077. 2001.
111. Cruz, DN, Brickel HM, Wysolmerski JJ, Gundberg CG, Simpson CA, Kliger AS, **Lorber MI**, Basadonna GP, Friedman AL, Insogna KL, Bia MJ. Treatment of osteoporosis & osteopenia in long term renal transplant patients with alendronate. Am. J. Transpl. 2:62-67. 2002.
112. Formica RN, Lorber KM, Friedman AL, Bia MJ, Lakkis F, SmithJD, **Lorber MI**. Sirolimus based immunosuppression with reduced dose cyclosporine or tacrolimus after renal transplantation. Transpl. Proc. 2002 (in Press).
113. Formica RN Jr, Friedman AL, Margaryan M, **Lorber MI**, Bia MJ. Use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treatment of hypertension appear to be safe and effective in the early post transplant period. Am J. Kidney Diseases. 2002. (Submitted).

B. BOOK CHAPTERS AND REVIEW ARTICLES:

114. Lancki, DW, **Lorber MI**, Loken, MR, and Fitch, FW: A clone specific monoclonal antibody which inhibits T cell mediated cytotoxicity. In Clark WR, and Goldstein, PR (eds.): Mechanism of Cell Mediated Cytotoxicity, pp. 557-562. Plenum Publishing Co., New York, 1982.
115. Campbell, DA, Jr., Dafoe, DC, and **Lorber MI**: Pathophysiology, prevention and assessment of renal failure in the critically ill patient. In Bartlett, RH, Whitehouse, W, Jr., and Turcotte, JG (eds.): Life Support Systems in Intensive Care, pp. 385-407. Year Book Medical Publishers, Chicago, 1984.
116. **Lorber MI** and Kahan, BD: Cyclosporine - an overview of recent advances. The Year in Immunology, pp. 182-192. Karger, Basel, 1985.
117. **Lorber MI**: Cyclosporine Action in Blockade of Cellular Immune Responses. The Year in Immunology 1985-1986. Karger, Basel, 279-288, 1986.
118. Flechner, SM, Conley, SB, Rose, G, Van Buren, C, Kerman, R, **Lorber MI** and Kahan, BD: Cyclosporine and prednisone immunosuppression in pediatric recipients of renal allografts. Wolff, ED, Provoost, AP, (eds). Cyclosporine in Pediatric Renal Transplantation. pp. 95-104; Foris Publishers. Dordrecht-Holland, and Providence-USA. 1986.
119. **Lorber,MI**: Renal Failure. In Miller, TA and Rowlands, BJ. The Physiologic Basis of Modern Surgical Care. pp. 706-719. CV Mosby Co, St. Louis, 1987.
120. **Lorber MI**: Toward Understanding the Mechanism of Cyclosporine Immunosuppression. The Year in Immunology. 3:291-302, Basel, Karger, 1988.
121. **Lorber MI**: The Mechanism of Cyclosporine Immunosuppression. The Year in Immunology. 4: 253-263, Karger, Basel; 1989.
122. **Lorber MI**. Cyclosporine: Lessons learned-Future Strategies. Clinical Transplantation. 5: 505-516. 1991.
123. **Lorber MI**. The Scientific Program. in History of the American Society of Transplant Surgeons. Salvatierra O, Lum CT, eds. Stanton Publications, Minneapolis. 1994.
124. Friedman AL, Basadonna GP, **Lorber MI**. The Living Kidney Donor. in The Multiorgan Donor: Selection and Management. Blackwell Scientific Publications, Inc. 1997.
125. Friedman AL, Navarro VJ, **Lorber MI**, Basadonna GP, Hefferon TG. The Living Liver Donor. The Multiorgan Donor: Selection and Management. Blackwell Scientific Publications, Inc. 1997.
126. **Lorber MI**, Basadonna GP, Friedman AL. Renal Transplantation: Surgical Technique and Management. The ASTP Primer on Transplantation. 1998.

127. **Lorber MI:** Renal Failure. In Miller, TA and Rowlands, BJ. The Physiologic Basis of Modern Surgical Care, 2nd Edition. Quality Medical Publishing. St. Louis. 1998.
128. Tellides G, Kirkiles NC, Tereb DA, Schechner JS, Wilson JH, Pober JS, **Lorber MI.** Transplantation Models in Human/Mouse Chimeras. in Timmerman W, Gassel H-J, Ulrichs K et al., eds. Organ Transplantation in Rats and Mice: Microsurgical Techniques and Immunological Principles. Berlin: Springer, 1998.
129. Friedman AL, Basadonna GP, **Lorber MI.** Elective and Emergency Surgery in the Stable Transplant Recipient. In Handbook of Organ Transplantation. Landes Bioscience Inc. 2000.
130. **Lorber MI,** Wang Y, Wilson J, Kirkiles-Smith N, Schechner JS, Geiselhart L, Tellides G, Pober JS. Human vascular rejection in PBL reconstituted SCID mice: Preliminary results using anti-IFN γ monoclonal antibody. In, A Festschrift Honoring Thomas Starzl. Fung K and Jordan M., eds. 2002.
131. Formica R, Friedman AL, **Lorber, MI.** The evolving role of sirolimus in organ transplantation. Current Opinion in Organ Transplantation. 7:353-358. 2002.

C. BOOK

Higgins RSD, Sanchez JA, **Lorber MI,** Baldwin JC. The Multiorgan Donor: Selection and Management. Blackwell Scientific Publications, Inc. 1997.

D. EDITORIALS AND BOOK REVIEWS:

1. **Lorber, MI:** Liver transplantation for fulminant hepatic failure. Hepatology. 8: 431. 1988.
2. **Lorber, MI:** Book Review: Liver Transplantation. 2nd Edition. Edited by Sir R.Y. Calne. 571 pp., Grune and Stratton, Inc., London, 1987. in Hepatology. 1988
3. **Lorber, MI:** Book Review: Transplantation of the Liver. Edited by Willis C. Maddrey, MD, 352 pp., Elsevier, New York, 1988. in Gastroenterology. 1988.
4. **Lorber, MI:** Invited Commentary: Brain Death and Organ Transplantation by Emiko Ohnuki-Tierney. Current Anthropology. 35: 233-254. 1994.
5. Burdick J, Caplan AL, Danovitch GM, Friedman EA, Gaston R, Gruessner R, Harmon W, Levey AS, London W, **Lorber MI,** Lundin AP, Miller LW, Mitch WE, Norman DJ, Port F. Consensus conference on standardized listing criteria for renal transplant candidates. Transplantation. 66: 1-6. 1998.

E. ABSTRACTS AND INVITED PRESENTATIONS:

1. **Lorber MI**, Campbell, DA, Jr., Wicks, JD, **Lorber MI**, Surance, P and Turcotte, JG. Etiology and management of early and late peritransplant fluid collections. Annual Meeting of the North Central Section of the American Urological Association. Bermuda, November 1980.
2. **Lorber MI**, Loken, MR, and Fitch, FW: IA antigens on cloned alloreactive T cells are acquired passively. Fed. Proc. 41-612, 1982.
3. Lancki, DW, **Lorber MI**, Loken, MR, and Fitch, FW: A clone specific monoclonal antibody which blocks cell mediated cytotoxicity. Fed. Proc. 41-609, 1982.
4. Campbell, DA, Jr, **Lorber MI**, Sweeton, JC, Turcotte, JG, and Beer, AE. Maternal donor related renal transplants: Influence of breast feeding on reactivity to the allograft. Presented at the Ninth International Congress of the Transplantation Society, Brighton, U.K., August 1982.
5. Lancki, DW, **Lorber MI**, Beller, DI, Vogel, SN, Prystowsky, MB, Loken, MR, and Fitch, FW: The effects of a clone specific monoclonal antibody on the function of a cytotoxic T lymphocyte clone. Fed. Proc. 42:831, 1983
6. Campbell, DA, Kois, WE, **Lorber MI**, Sweeton JC and Dafoe, DC. Influence of breast feeding on subsequent reactivity to a related renal allograft. Association for Academic Surgery, Syracuse, New York, November 1983.
7. Dafoe, DC, Campbell, DA, **Lorber MI**, Berlin, RE, Kahn, LE, Lovett, EJ, Hudson, JL: Assessment of elutriation in islet cell preparation from porcine pancreas. Diabetes 33 (Suppl. 1): 181A, 1984.
8. **Lorber MI**. A sixteen year experience with subtotal parathyroidectomy for secondary hyperparathyroidism. Presented at the 30th Clinical Meeting of the Frederick A. Collier Surgical Society, Carmel, California, October 1984.
9. DC Dafoe, WH Marks, **MI Lorber**, DA Campbell, Jr., T-cell subset patterns in renal transplant recipients with CMV disease. Presented at the Annual Meeting of the Association for Academic Surgery San Antonio, Texas, November 1984.
10. **Lorber MI**, Flechner, SM, Van Buren, CT, Kerman, RH, Bartosh, J, and Kahan, BD: Cyclosporine Toxicity: The effect of combined therapy using cyclosporine, azathioprine, and prednisone. Hum. Immunol. 13:59-60, 1985.
11. Flechner, SM, Van Buren, CT, **Lorber MI**, Kerman, RH, Wideman, C, and Kahan, BD: Does cyclosporine influence the results of cadaver retransplantation? Hum. Immunol. 13:53-54
12. Kerman, RH, Van Buren, CT, Flechner, SM, **Lorber MI** and Kahan, BD: Successful transplantation of cyclosporine-treated allograft recipients with serologically positive historical but negative preoperative donor crossmatches. Hum. Immunol. 13:57, 1985.

13. **Lorber MI.** Cyclosporine toxicity: The effect of combined therapy using cyclosporine azathioprine, and prednisone. Presented at the Annual Meeting of the American Society of Transplant Physicians, Chicago, Illinois, May, 1985.
14. Jarowenko, M, Flechner, S, Van Buren, CT, **Lorber MI**, and Kahan, BD: Influence of cyclosporine on post-transplant blood pressure response. Presented at the Annual Meeting of the American Society of Transplant Physicians, Chicago, Illinois, May, 1985.
15. Flechner, SM, Sandler, C, Van Buren, CT, **Lorber MI** and Kahan, BD: 100 Living related kidney donor evaluations using digital subtraction angiography. Presented at the Annual Meeting of the American Society of Transplant Surgeons, Chicago, Illinois, May 1985.
16. **Lorber MI.** Prevention and management of acute renal failure following multiple trauma. Invited lecture, the Graduate Nursing Seminar on Trauma, University of Texas Health Science Center at Houston, April 9, 1986.
17. **Lorber MI.** Drug interactions with immunosuppressive medications. Invited lecture at Issues in Transplantation, 1986. Nashville, Tennessee, April 17, 1986.
18. **Lorber MI.** Immunosuppression in extrarenal transplantation. Invited lecture at Surgical Grand Rounds, Loyola University Medical School, Maywood, Illinois, April 23, 1986
19. **Lorber MI.** Cyclosporine in heart and heart-lung transplantation. Chairman of Session, Sixth Scientific Sessions of the International Society for Heart Transplantation, New York, New York, April 27, 1986.
20. Kerman, RH, Flechner, SM, Van Buren, C, **Lorber MI**, Dawson, G, Falk, L, and Kahan, BD: Investigation of HTLV-3 serology in a renal transplant population. Annual Meeting of the American Society of Transplant Physicians, Chicago, Illinois, May 27, 1986.
21. **Lorber MI**, Van Buren, CT, Flechner, SM, Cameron, L, Leatherwood, J, Walker, WE, Smalling, RW, and Kahan, BD: Pretransplant coronary arteriography to minimize the effects of coronary atherosclerosis in diabetic renal transplant recipients. Annual Meeting of the American Society of Transplant Physicians. Chicago, Illinois, May 27, 1986.
22. Flechner, SM, Van Buren, C, Kerman, R. **Lorber MI**, and Kahan, BD: Does cyclosporine improve the results of renal transplantation for HLA-identical recipients? Annual Meeting of the American Society of Transplant Physicians, Chicago, Illinois, May 27, 1986.
23. Kerman, RH, Flechner, SM, Van Buren, CT, **Lorber MI**, Bergh, OJ, and Kahan, BD: Immunoregulatory mechanisms in cyclosporine-renal allograft recipients. Annual Meeting of the American Society of Transplant Physicians, Chicago, Illinois, May 27, 1986.
24. Kahan, BD, **Lorber MI**, Flechner, SM, Golden, D, and Van Buren, CT: Complications of cyclosporine therapy in 400 renal allografted patients followed 1-5 years. Annual Meeting of the American Society of Transplant Physicians, Chicago, Illinois, May 27, 1986.

25. Kahan, BD, Mickey, R, Flechner, SM, **Lorber MI**, Wideman, CA, Kerman, RH, Terasaki, P, and Van Buren, CT: Multivariant analysis of risk factors impacting on immediate a eventual cadaver allograft survival in cyclosporine-treated patients. Annual Meeting of the American Society of Transplant Surgeons, Chicago, Illinois, May 29, 1986.
26. Colon, R, **Lorber MI**, Frazier, OH, Radovancevic, B, Van Buren, CT, McAllister, HA, Kahan, B.D, and Cooley, DA: An alternative approach to the therapy of rejection in cardiac allograft recipients. Annual Meeting of the American Society of Transplant Surgeons, Chicago, Illinois, May 30, 1986.
27. Frazier, OH, Radovancevic, B, **Lorber MI**, Colon, R, Van Buren, CT, Kahan, BD, Cooley, DA: Cardiac transplantation in patients over 55 years of age. Annual Meeting of the American Society of Transplant Surgeons, Chicago, Illinois, May 30, 1986.
28. **Lorber MI**, Van Buren, CT, Flechner, SM, Williams, C and Kahan, BD: Hepatobiliary complications of cyclosporine therapy in renal transplantation. Annual Meeting of the American Society of Transplant Surgeons, Chicago, Illinois, May 30, 1986.
29. Cameron, L, Leatherwood, J, Walker, WE, Smalling, RN, **Lorber MI**: Pretransplant coronary arteriography for diabetic renal transplant recipients. XI International Congress of the Transplantation Society. Helsinki, Finland. August 3, 1986.
30. Sorenson, K, **Lorber MI**: Management of Immunosuppressive problems in renal allograft recipients. XI International Congress of the Transplantation Society. Helsinki, Finland. August 3, 1986.
31. Van Buren, CT, Burstain, TL, Frazier, OH, Schnee, MJ, Kerman, RH, **Lorber MI**, Colon, R, McAllister, H, Kahan, BD: Predictors of rejection in cyclosporine treated cardiac recipients. XI International Congress of the Transplantation Society. Helsinki, Finland, August 3, 1986.
32. **Lorber MI**, Williams, C, Van Buren, CT: Hepatobiliary complications cyclosporine therapy in renal transplantation. XI International Congress of the Transplantation Society. Helsinki, Finland, August 3, 1986.
33. **Lorber MI**. Cyclosporine immunosuppression in organ transplantation. Invited lecture at Nephrology Grand Rounds. Brown University School of Medicine. Providence, RI. November 21, 1986.
34. **Lorber MI**. Immunologic monitoring in clinical organ transplantation. Invited lecture, Clinical Immunology Seminar. Yale University School of Medicine. New Haven, CT January 9, 1987.
35. **Lorber MI**. Organ transplantation in children. Invited lecture, Recent Advances in Pediatrics for the Practitioner. University of Connecticut School of Medicine. Farmington, CT June 3, 1987.
36. **Lorber MI**. Cyclosporine Immunosuppression in Organ Transplantation. Visiting Professor. University of Ottawa School of Medicine. Ottawa, Ontario, Canada June 9-10, 1987.

37. **Lorber MI.** Organ Transplantation: an update. Invited lecture, Advances in Medicine Series, Lawrence and Memorial Hospital, New London, CT. September 29, 1987
38. **Lorber MI.** Experience with monoclonal antibodies in organ transplantation. Invited Plenary Speaker, The 5th Panhellenic Congress of the Hellenic Transplantation Society. Volos, Greece. October 17, 1987.
39. **Lorber MI.** Recent advances in immunosuppression for human organ transplantation. Invited panel discussion: The 5th Panhellenic Congress of the Hellenic Transplantation Society. Volos, Greece. October 17, 1987.
40. **Lorber MI.** An overview of renal and hepatic transplantation. Invited lecture at a special symposium on progress in transplantation, at the Congress of Neurological Surgeons Annual Meeting. Baltimore, MD. October 27, 1987.
41. **Lorber MI.** Progress in Transplantation and the Neurosurgeon's Practice. Invited Lecture. American Association of Neurological Surgeons Annual Meeting. Toronto, Ontario. April 27, 1988.
42. **Lorber MI.** A new era in surgical transplantation and immunosuppression therapy. Invited Lecture - Surgical Grand Rounds, Columbia University College of Physicians and Surgeons, St. Luke's Hospital, New York, New York, May 18, 1988.
43. Bia MJ, Pachon, J, **Lorber MI.** Histamine H₂ Receptor Antagonists do not exacerbate cyclosporine nephrotoxicity. American Society of Transplant Physicians Annual Meeting, June 1, 1988.
44. **Lorber MI.** Toward an Individualized approach to immunosuppression following Organ Transplantation; Columbia University College of Physicians & Surgeons, Presbyterian Hospital; September 27, 1988; Visiting Professor.
45. **Lorber MI.** American Society of Transplant Physicians, Consensus Conference on the Prophylactic Use of Monoclonal Antibody Therapy in Organ Transplantation; St. Louis, Missouri; October 21, 1988; Invited Participant.
46. **Lorber MI.** Immune System Modulation - Nutritional and Pharmacological Approaches; J. Wesley Alexander, M.D. and Robert A. Good, M.D., PhD., Symposium Chairmen; Palm Springs, California; November 3-6, 1988; Invited Participant.
47. Marks WH, Harding MW, Marks C, Lorber MI. The tissue distribution of cyclophilin, a primary mediator of cyclosporine actions. The American Society of Transplant Physicians Annual Meeting. Chicago, Illinois. May 30, 1989.
48. **Lorber MI.** Long term selective immunosuppressive therapy for organ transplant patients. Invited Participant on advisory panel. New York, New York. September 5-6, 1989.
49. **Lorber MI.** International Consensus Workshop on Cyclosporine Monitoring. Invited Speaker. Hawks Cay, Florida. January 13-17, 1990.

50. **Lorber MI.** Immunosuppression for Organ Transplantation. American Nephrology Nurses Association; Invited Speaker; Washington, DC, April 24, 1990.
51. **Lorber MI.** A strategy for individualized immunosuppression following organ transplantation. Annual Organ Transplantation Symposium, The Methodist Organ Transplant Center, Dallas, TX. Invited Faculty. April 26, 1990.
52. Paul, K, Harding, MW, Marks, WH, Handschumacher, RE, **Lorber MI,** Quantitative recovery of cyclosporine and cyclosporine metabolites from whole blood using an assay based on cyclophilin binding. Annual Meeting, American Society of Transplant Physicians. May, 1990. Chicago, Illinois.
53. **Lorber MI,** Wilson, JH, Harding, MW, Marks, WH. A comparison of in vivo response to cyclosporine and rapamycin following allogeneic immune challenge. Annual Scientific Meeting, American Society of Transplant Surgeons. June, 1990. Chicago, Illinois.
54. **Lorber MI.** Clinical Protocols for maintenance anti-rejection therapy following renal transplantation; First Annual Postgraduate Course, The American Society of Transplant Surgeons. Invited Faculty. June, 1990; Chicago, Illinois.
55. **Lorber MI.** Cyclophilin Binding; a more biologically relevant approach to dosing of cyclosporine immunosuppression. Wyeth-Ayerst Research Laboratories. Invited Speaker. July 16, 1990; Princeton, New Jersey.
56. **Lorber MI.** In Vivo effects of Cyclosporine and Rapamycin after allogeneic immune challenge. Invited Speaker. First International Symposium on Rapamycin Immunosuppression. August, 18, 1990. San Francisco, California.
57. Paul, K, Harding, MW, Marks, WH, Handschumacher, RE, **Lorber MI.** Cyclophilin binding represents a more accurate measure of cyclosporine immunosuppressive activity after renal transplantation. Eighteenth International Congress of the Transplantation Society. August, 1990, San Francisco, California.
58. Marks, WH, Borgstrom, A, Marks, CR, **Lorber MI.** Serum markers for pancreas rejection: Long term behavior following clinical pancreatico-duodenal transplantation. Eighteenth International Congress of the Transplantation Society. August, 1990, San Francisco, California.
59. **Lorber MI.** The case for Cyclophilin as the biologically relevant receptor responsible for cyclosporine immunosuppression. Visiting Professor. Section of Pediatric Nephrology. University of California at Los Angeles. August 29,1990.
60. **Lorber MI.** The Immunobiology of Pulmonary Transplantation. Invited Address; Annual Scientific Meeting of the American Lung Association of Connecticut. Southbury, Connecticut. October 2, 1990.
61. **Lorber MI.** Cyclosporine Monitoring after Organ Transplantation. Annual New England Workshop. The American Society for Clinical Chemistry. Hartford, CT. October 18, 1990.

62. Gromkowski, SH, Levi, EK, **Lorber MI**. Exogenous ATP Facilitates TNG-Mediated Cell lysis - a novel mechanism of killing by inflammatory T Cells? The 3rd International Conference on Tumor Necrosis Factor and Related Cytokines. Chiba, Japan. November 24, 1990.
63. **Lorber MI**. Organ Transplantation; Past and present success, future responsibilities. Visiting Professor, Abington Memorial Hospital & Temple University Medical Center. Philadelphia, PA. May 3-4, 1991.
64. Richard, E, **Lorber MI**, Marks, WH, Bia, MJ. Are calcium channel blockers protective against first dose reactions to OKT3. Annual Meeting of the American Society of Transplant Physicians. Chicago, IL. May 28, 29, 1991.
65. SanFilippo, FP, Vaughn, WK, Peters, TG, Shield, CF,III, Adams, PL, **Lorber MI**, Williams, GM. Factors affecting the waiting time of candidates for cadaver donor kidney transplantation in the United States. Annual Meeting of the American Society of Transplant Physicians. Chicago, IL, May 28,29, 1991.
66. Perkal, MF, **Lorber, MI**, Marks, WH. A three year clinical experience using serum anodal trypsinogen, a biochemical marker for rejection in pancreatic allografts: false positives, tissue biopsy, comparison to other markers and diagnostic strategies. Annual Meeting of the American Society of Transplant Surgeons. Chicago, IL, May 30, 1991.
67. McDonald, ML, Ardito, T, Marks, WH, Kashgarian, M, **Lorber, MI**. The effect of cyclosporine therapy on the cellular distribution and content of cyclophilin. Annual Meeting of the American Society of Transplant Surgeons. Chicago, IL, May 30, 1991
68. **Lorber MI**. Cyclosporine; Second Annual Postgraduate Course, The American Society of Transplant Surgeons. Invited Faculty. June, 1991; Chicago, Illinois.
69. Brusett, K, Marks, WH, **Lorber, MI**. N-tosyl-L-lysyl-chloromethylketone (TLCK) or N-p-tosyl-phenylalanineketone (TPCK) inhibition of T cell activation. Resident's Section, Society of University Surgeons. Cincinnati, 1992.
70. Powelson, JA, Jenkins, RL, Lewis, D, Rohrer, RJ, **Lorber, MI**, Cosimi, AB. Hepatic retransplantation: A regional experience. Annual Meeting, American Society of Transplant Surgeons. Chicago, IL. May 29, 1992.
71. Azhderian, E, Lentz, S, Vives, K, **Lorber, MI**, Identification of nuclear membrane associated immunophilins of potential importance in cyclosporine and FK506 immunosuppression. Annual Meeting, American Society of Transplant Surgeons. Chicago, IL. May 28, 1992.
72. Cosimi, AB, Powelson, JA, Lewis, D, Rohrer, RJ, Freeman, RB, Vacanti, J, Jonas, M, **Lorber, MI**, Marks, WH, Jenkins, RL. Hepatic Retransplantation: A regional experience. XIV International Congress of the Transplantation Society, Paris, France, August 19, 1992.

73. Azhderian, E, Lentz, S, **Lorber, MI**. Nuclear associated cyclophilins of potential importance in cyclosporine immunosuppression. XIV International Congress of the Transplantation Society, Paris, France, August 18, 1992.
74. **Lorber, MI**, Vives, K, Azderian, E. Nucleus associated FK506 binding proteins with potential relevance to FK506 immunosuppression. XIV International Congress of the Transplantation Society, Paris, France, August 17, 1992.
75. **Lorber MI**. Transplantation: Advances in long- term care. American Kidney Fund Symposium, Clinical Strategies for the 1990's. Invited Faculty. Natick, Massachusetts. October 8, 1992.
76. **Lorber MI**. Organ Transplantation: Winning the battle - are we winning the war? Visiting Professor, SUNY - Syracuse. December 8-9, 1992.
77. Morrissey, PE, Gollin, G, Brusett, K, **Lorber, MI**, Marks, WH. TLCK, a serine protease inhibitor prolongs heterotopic cardiac allograft survival in the rat. American Society of Transplant Physicians, Houston, TX. 1993.
78. Morrissey, PE, **Lorber, MI**, Marks, WH. Calcium channel blockers do not exhibit *in vivo* immunosuppression. American Society of Transplant Physicians. Houston, TX. 1993.
79. Bia, MJ, Cheng, S, **Lorber, MI**. Microalbuminuria in stable renal transpant patients. Frequency and clinical correlation. American Society of Transplant Physicians. Houston, TX. 1993.
80. Morrissey, PE, Lorber, KM, Marcarelli, M, Bia, MJ, Kliger, AS, **Lorber, MI**. Post transplant Epstein Barr virus infection is associated with elevated levels of CD19⁺ B cells. Annual Scientific Meeting, American Society of Transplant Physicians. Chicago, IL. May 18, 1994.
81. **Lorber, MI**, Morrissey, PE, Lorber, KM et al. Immunologic monitoring after transplantation: Relationship between Epstein Barr virus infection & CD19⁺ B Cells measured by flow cytometry. XV World Congress of the Transplantation Society. Kyoto, Japan. August 30, 1994.
82. Friedman, AL, Eyer, J, **Lorber, MI**, et al. Practical limits to pre- transplant screening for hepatic cancer. Hepatology. 20: 348A. 1994.
83. Auersvald LA, **Lorber MI**, Friedman AL, Bia MJ, Mahnensmith RL, Kliger AS, Basadonna GP. Hypertension: a risk factor for chronic rejection in renal transplantation. Int. Symposium on the Etiology and Pathobiology of transplant vasclular sclerosis. Bermuda. March 1, 1995.
84. Leichtman, AB for the OG 37-325 Study Group. OG 37-325 is equally efficacious to but more hepatotoxic than Cyclosporin A. 1995 Internatiional Consensus Conference on Immunosuppressive Drugs. Lake Louise, Canada. May 6, 1995.
85. Auersvald, LA, Perez, RV, **Lorber, MI**, Struges, M, Friedman, AL, Bia, MJ, Orias, M, Wilson, J, Ezhderian, E, Gruber, J, Basadonna, GP. Serum sialic acid, a risk factor for cardiovascular disease, improves following pancreas transplantation. Fifth International Pancreas and Islet Transplantation Association Congress, 1995.

86. Leichtman, AB for the OG 37-325 Study Group. OG 37-325 demonstrates equivalent efficacy to Cyclosporin A: Report of two Phase III multicenter trials. Annual Meeting, The American Society of Transplant Physicians. May 17, 1995.
87. Auersvald, LA, **Lorber, MI**, Friedman, AL, Bia, MJ, Kliger, AS, Basadonna, GP. Immunologic and Non- immunologic factors in the development of chronic allograft nephropathy. Annual Meeting, The American Society of Transplant Physicians. May 16, 1995.
88. Friedman, AL. Basadonna, GP,. Kliger, AS, Bia, MJ, **Lorber, MI**. Must living renal donors be hospitalized overnight prior to surgery? Annual Meeting, The American Society of Transplant Physicians. May 16, 1995.
89. Friedman, AL, **Lorber, MI**, Basadonna, GP, Gruber, J, Barker, CF, Grossman, R, Bia, MJ, Kliger, AS, Holland, T. Morbid obesity does not preclude safe or successful renal transplantation. Annual Meeting, The American Society of Transplant Physicians. May 16, 1995.
90. Murray, AG, Epperson, DE, Madson, J, Hughes, CCW, **Lorber, MI**, Askenase, PA, Pober, JS. Cyclosporine A immunosuppression in the huPBL/SCID-allogeneic skin graft model. Annual Meeting, The American Society of Transplant Physicians. May 17, 1995.
91. Lignelli A, **Lorber MI**, Kliger AS, Bia MJ, Basadonna GP, Friedman AL. Recent hernia repair does not preclude peritoneal dialysis. American Society for Artificial Internal Organs. Chicago, IL. May 5, 1995.
92. Washburn, WK, Bradley, J, Cosimi, AB, Freeman, RB, Hull, D, Jenkins, RL, Lewis, WD, **Lorber, MI**, Rohrer, RJ, Schweitzer, RJ, Vacanti, JP. A regional experience with emergency liver transplantation. Annual meeting, American Society Transplant Surgeons. May 19, 1995.
93. Auersvald LA, **Lorber, MI**, Friedman AL, Basadonna GP. Circulating plasminogen activator inhibitor-1 (PAI-1) does not correlate with chronic allograft nephropathy in renal transplantation. Basic Sciences Symposium of the Transplantation Society. Noordwijerhour, The Netherlands. September 17-20, 1995.
94. Murray A, Sultan P, Madison J, Hughes C, Epperson D, Askenase P, **Lorber M**, Bothwell P, Pober J. Human anti- porcine xenogeneic reactions in the chimeric huPBL- SCID mouse: initiation of graft injury by porcine interferon- G. The Third International Congress for Xenotransplantation. Boston, MA. September, 1995.
95. **Lorber, MI**, Basadonna, GP, Friedman, AL, Lorber, KM, Marcarelli M, Bia MJ, Kliger AS. Reduced incidence of EBV associated post transplant lymphoproliferative disease among high risk recipients using prophylactic ganciclovir. Frederick A. Collier Surgical Society. Bolton Landing, New York. October 8, 1995.
96. **Lorber MI**. Cybercongress: Transplantation in the next millennium. Invited Faculty. Washington, D.C. November 13-15, 1995.

97. **Lorber MI.** New Strategies for Immunosuppression in Organ Transplantation. Visiting Professor. University Vermont College of Medicine. Burlington, Vermont. January 18, 1996.
98. **Lorber, MI.** Patient Selection in Renal Transplantation. Listing and Priority Criteria. Third Annual Forum on Transplantation; UNOS / HRSA Division of Organ Transplantation. Washington, D.C. February 21, 1996.
99. **Lorber MI.** Receptor based monitoring in clinical organ transplantation. Invited Lecture. Triboro Surgical Rounds. SUNY Med. Center, Downstate; Brooklyn, N.Y. Feb. 29, 1996.
100. **Lorber MI, Basadonna GP, Friedman AL, Lorber KM, Marcarelli M, Bia M, Kliger AS.** Toward reducing the incidence of post transplant viral infection. Horizons in Transplantation. Grand Cayman Island. Invited Lecture. April 12, 1995.
101. Lee LS, Auersvald LA, Bia MJ, Friedman AL, **Lorber MI**, Basadonna GP. Association between donor and recipient body surface area and the development of chronic rejection in renal transplantation. Annual Mtg. Am. Soc. Transplant Physicians. Dallas TX. May 28, 1996.
102. Lee LS, Auersvald LA, Friedman AL, **Lorber MI**, Basadonna GP. Noncompliance as a cause of renal graft failure. Ann. Mtg. Am. Soc. Transplant Physicians. Dallas Texas. May 28, 1996.
103. Kerman RH, Orosz CG, **Lorber MI.** Clinical relevance of anti-HLA antibodies pre- and post-transplantation. Invited Symposium. Annual Meeting of the American Society of Transplant Physicians. Dallas Texas. May 29, 1996.
104. Auersvald LA, Friedman AL, **Lorber MI**, Basadonna GP. Pancreas after kidney transplantation in type I diabetic recipients: High success rate is independent of poor HLA matching. International Assoc. of Pancreatology. Mannheim, Germany. June 13, 1996.
105. Basadonna GP, Auersvald LA, Friedman AL, **Lorber MI.** Pancreas after kidney transplantation. HLA mismatch does not preclude success. XVI International Congress of the Transplantation Society. Barcelona, Spain. August 26, 1996.
106. Lee LS, Auersvald LA, Claus EB, Bia MJ, Friedman AL, **Lorber MI**, Basadonna GP. Body size mismatch between donor and recipient & development of chronic rejection in renal transplantation. XVI Internat. Congress, Transpl. Society. Barcelona, Spain. August 27, 1996.
107. Kerman RH, Orosz CG, **Lorber MI.** Clinical relevance of anti-HLA antibodies pre- and post-transplantation. Invited Symposium. 16th International Congress of the Transplantation Society. Barcelona, Spain. August 27, 1996.
108. Cruz DN, Lee FA, Sinusas AJ, Basadonna GP, Friedman AL, **Lorber, MI**, et al. Evaluation of progression of coronary artery disease in diabetic patients awaiting renal transplantation. Annual Meeting of the American Society of Transplant Physicians. Chicago, Illinois. May 12, 1997.
109. Darenkov IA, Basadonna GP, Friedman AL, Lorber KM, Marcarelli MA, Bia MJ, Kliger AS, **Lorber MI.** Prophylactic antiviral therapy reduces the incidence of EBV associated post

- transplant lymphoproliferative disorder after solid organ transplantation. Annual Meeting of the American Society of Transplant Surgeons. Chicago, Illinois. May 15, 1997.
110. Friedman AL, Goker O, Kalish M, Basadonna GP, Kliger AS, Bia MJ, **Lorber MI**. Diminished immune activity correlates with a low risk of rejection in renal transplant recipients over age 60. Annual Meeting of the American Society of Transplant Surgeons. Chicago, Illinois. May 16, 1997.
 111. Kasiske B, Levy A, Matas A, **Lorber, MI**. Listing Patients for Cadaveric Renal Allografts: Who and When? Invited Panelist, 30th Annual of the American Society of Nephrology. San Antonio, TX. November 5, 1997.
 112. **Lorber MI**. Donor and Recipient Factors Influencing Renal Allograft Survival. Annual Postgraduate Course, New York Transplant Programs. New York University School of Medicine. New York, New York. December 4, 1997.
 113. Pober J, Schechner J, Murray A, Sultan P, Kirkiles N, Tereb D, Wilson J, McNiff J, Askenase P, Tellides G, **Lorber MI**. Allogeneic and xenogeneic vascular injury and protection. Third International Conference on New Trends in Clinical and Experimental Immunosuppression. Geneva, Switzerland. February 15. 1998.
 114. **Lorber MI**. New Dimensions in Transplantation; Weaving the Future. Invited Faculty. Florence, Italy. February 16-18, 1998.
 115. **Lorber MI**. The Clinical Use of anti-IL2r Monoclonal Antibodies with Novel Immunosuppressive Agents. Annenberg Conference; The Evolving Role of de novo Treatment Protocols in Renal and Hepatic Transplantation. The Annenberg Center. Rancho Mirage, California. February 28 – March 1, 1998.
 116. Johnson MM, Mahnensmith R, Brickel H, **Lorber MI**, Basadonna GP, Friedman AL. Patient demographics influence the choice of primary vascular access for hemodialysis in an inner city population. 44th Annual Conference ASAIO. New York, New York. April 23-35, 1998.
 117. Venkat A, **Lorber MI**, Navarro VJ, Friedman AL. Severity of illness among long waiting liver transplant candidates. 17th Annual Scientific Meetings of the American Society of Transplant Physicians. Chicago, IL. May 10-13, 1998.
 118. **Lorber MI**, Evans C, Fastenau J, DiCesare J, Hall M. An economic evaluation of basiliximab for the prevention of acute rejection in renal allograft recipients. 17th Annual Scientific Meetings of the American Society of Transplant Physicians. Chicago, IL. May 10-13, 1998.
 119. Pruett TL, **Lorber MI**, Wright FH, Pescovitz M. Pharmacokinetics and Safety of MEDI-507, a humanized monoclonal antibody directed against CD-2 in renal allograft recipients. 24th Annual Meetings of the American Society of Transplant Surgeons. Chicago, IL. May 13-15, 1998.
 120. Delmonico F, Harmon W, **Lorber MI**, Goguen J, Mah H, Himmelfarb J, Lipkowitz G, Valliere S, Milford E, Rohrer R. A new allocation plan for renal transplantation. 24th Annual Meeting of the American Society of Transplant Surgeons. Chicago, IL. May 13-15, 1998.

121. **Lorber MI**, Wilson JH, Robert ME, Schechner JS, Kirkiles N, Quian HY, Askenase PW, Tellides G, Pober JS. Vascular rejection after arterial transplantation and lymphoid reconstitution in SCID mice. 24th Annual Meetings of the American Society of Transplant Surgeons. Chicago, IL. May 13-15, 1998.
122. **Lorber MI**. Maximizing Organ Donation; is the national allocation debate helping? 30th Anniversary Celebration of the New England Organ Bank. The John F. Kennedy Library. Boston, Massachusetts. November 30, 1998.
123. Woodle ES and **Lorber MI**. Controversial Issues in Organ Transplantation. Session Chair. Annual Winter Meeting, American Society of Transplant Physicians. Kapalua, Hawaii. January 17, 1999.
124. **Lorber MI**. Alloimmune Vascular Injury in Organ Transplantation. Invited Presentation. Annual Meeting, Hong Kong Society of Transplantation. Kowloon, Hong Kong. April 11, 1999.
125. **Lorber MI**. Toward Developing a New Paradigm for Immunosuppression after Organ Transplantation. Plenary Lecture. Annual Meeting, Hong Kong Society of Transplantation. Kowloon, Hong Kong. April 11, 1999.
126. Delmonico F, Milford E, Goguen J, Harmon W, Bow L, Lipkowitz G, Himmelfarb J, Rohrer R, and **Lorber MI**. A novel UNOS region kidney allocation plan improves transplant access for minority candidates. Annual Scientific Meetings of the American Society of Transplantation. Chicago, Illinois. May 16, 1999.
127. Tereb D, Kirkiles NC, Kim RW, Pober JS, **Lorber MI**, and Tellides G. Large animal coronary artery endothelial expression of MHC molecules is not constitutive. Annual Scientific Meetings of the American Society of Transplant Surgeons. Chicago, Illinois. May 21, 1999.
128. **Lorber MI**. Alloimmune arterial injury after organ transplantation; sirolimus as a potential therapeutic strategy. The Harry DeLozier Invited Lecturer. The Ohio State University Medical Center. Columbus, Ohio. June 4, 1999.
129. **Lorber MI**. Immunosuppressive management among patients with delayed graft function after renal transplantation. Invited Plenary Lecture. Korean Society of Transplantation. Seoul, Korea. October 8, 1999.
130. **Lorber MI**. Anti- IL2R antibody therapy in combination with cyclosporine and corticosteroids in renal transplantation. Invited Plenary Lecture. Korean Society of Transplantation. Seoul, Korea. October 8, 1999.
131. **Lorber MI**. Sirolimus Versus Azathioprine in Combination With Cyclosporine and Prednisone in Primary Renal Transplants: A Pivotal Phase III Multicenter, Randomized, Double Blind Trial. Minneapolis Transplant Congress. Minneapolis, Minnesota. October 21, 1999.

132. **Lorber MI.** An evolving paradigm for immunosuppression after organ transplantation. Invited lecture. Medical College of Virginia, Richmond, Virginia. December 9, 1999.
133. **Lorber MI.** Alloimmune vascular injury in organ transplantation. Inaugural Invited Lecturer. Cornell-Columbia Immunobiology and Transplantation Seminar. NY, NY. January 4, 2000
134. **Lorber MI.** Alloimmune arterial injury in organ transplantation. Visiting Professor, University of Missouri Medical School, Columbia, Missouri. March 22, 2000
135. **Lorber MI.** New strategies for immunosuppression after organ transplantation. Visiting Professor. St. Louis University Medical School. March 23, 2000
136. Kovarik JM, Rordorf C, Kahan BD, Kaplan B **Lorber MI**, and the RADB 157 Study Group. Longitudinal assessment of the steady state pharmacokinetics of RAD in *de novo* renal transplant
137. Kahan BD, Kaplan B, **Lorber MI**, and the RADB 157 Study Group. Multicenter randomized, double blind dose finding study evaluating the efficacy and safety of RAD001 in de novo renal transplant recipients. *Transplantation*. 69 (suppl): s359. 2000
138. Tereb DA, Kirkiles-Smith NC, Kim RW, Pober JS, **Lorber MI**, Tellides G. Human T cells do not infiltrate or injure pig coronary artery grafts in immunodeficient mouse hosts. *Transplantation*. 69 (suppl): s384. 2000.
139. Tereb DA, Kirkiles-Smith NC, Kim RW, **Lorber MI**, Pober JS, Tellides G. Human T cells do not infiltrate or injure Pig coronary artery grafts in immunodeficient mouse hosts. 18th International Congress of the Transplantation Society, Rome, Italy, August 28, 2000
140. Kirkiles-Smith NC, Tereb DA, Kim RW, McNiff JM, Schechner JS, **Lorber MI**, Pober JS, Tellides G. Human TNF can induce nonspecific inflammatory and human immune mediated microvascular injury of pig xenografts in immunodeficient mouse hosts. 18th International Congress of the Transplantation Society, Rome, Italy, August 29, 2000
141. Kim RW, Tereb DA, Kirkiles-Smith NC, Mahboubi K, **Lorber MI**, Pober JS, Tellides G. PDGF inhibits IFN γ mediated MHC class I antigen expression in coronary arteries. 18th International Congress of the Transplantation Society, Rome, Italy, August 30, 2000
142. Rordorf C, Kovarik JM, Kahan BD, Kaplan, **Lorber MI**, et al. Steady state disposition of RAD in 91 *de novo* renal transplant patients assessed longitudinally over a 6 month period. 18th International Congress of the Transplantation Society, Rome, Italy, August 30, 2000
143. Rordorf C, Kovarik JM, Kahan BD, Kaplan, **Lorber MI**, et al. Double blind, longitudinal assessment of the influence of RAD on cyclosporine pharmacokinetics in 87 *de novo* renal transplant patients. 18th International Congress of the Transplantation Society, Rome, Italy, August 30, 2000
144. Kahan BD, Kaplan B, **Lorber MI**, et al. Safety and preliminary efficacy of RAD in de novo renal transplant recipients evaluated in a multicenter, randomized, double blind, dose finding study. 18th International Congress of the Transplantation Society, Rome, Italy, Sept. 1, 2000.

145. **Lorber MI.** An evolving paradigm for immunosuppression after organ transplantation. Visiting Professor. State University of New York – Upstate. Syracuse, New York. September 19, 2000.
146. B Kaplan, BD Kahan, **MI Lorber**, et al. One year efficacy and safety outcomes with RAD in *de novo* renal transplantation. 33rd Annual Scientific Meetings of the American Society of Nephrology. October 13, 2000
147. **Lorber MI.** Alloimmune vascular injury in organ transplantation. Invited Lecture, Northwestern University Medical School. Chicago, Illinois. October 19, 2000
148. **Lorber, MI.** Alloimmune arterial injury in organ transplantation. Invited Lecture, The University of Cincinnati School of Medicine. Cincinnati, Ohio. February 27, 2001
149. **Lorber MI.** AST Consensus Conference on Generic Drug Substitution in Immunosuppression. Invited Speaker. St. Louis, Missouri. February, 28, 2001
150. **Lorber MI.** Individualization of Immunosuppressive Therapy. Adjunctive Therapy. Invited Review. Satellite pre- Symposium. Transplant 2001. Chicago, Illinois. May 12, 2001
151. **Lorber MI.** Clinical Trials in Immunosuppression: TOR and/or Calcineurin Inhibitors. Invited Plenary Review. Transplantation 2001. The Joint Meetings of the American Society of Transplantation and American Society of Transplant Surgeons. May 13, 2001
152. Vincenti F, Mendez R, Rajagopalan PR, Wilkinson A, Butt K, Laskow D, Slakey D, **Lorber MI**, Pescovitz MD, Dedrick R, Walicke P, Garovoy MR. A phase I/II Trial of anti- CD11a Monoclonal Antibody in Renal Transplantation. Transplantation 2001. The Joint Meetings of the Am. Society of Transplantation & American Society of Transplant Surgeons. May 14, 2001.
153. Freeman RB, Rohrer RJ, Katz E, Lewis WD, Jenkins R, Cosimi AB, Delmonico FL, Friedman A, **Lorber MI.** Preliminary results of a liver allocation plan using a continuous medical severity score that de- emphasizes waiting time. Transplantation 2001. The Joint Meetings of the Am. Society of Transplantation and American Society of Transplant Surgeons. May 14, 2001.
154. **Lorber MI.** The Non- Directed Living Donor. Invited Panelist. The National Kidney Foundation Symposium. Boston, Massachusetts. May 30-31, 2001.
155. **Lorber MI.** Transplant Study Design; Clinical Trials Endpoints. Invited Panelist. The American Society of Transplant Surgeons. Washington, D. C. June 5, 2001.
156. **Lorber MI**, Troncoso P. Invited Session co- Chairs. Ischemia – Reperfusion Injury. 2001 A Transplant Odyssey. Istanbul, Turkey. August 22, 2001.
157. **Lorber MI.** The evolving role of TOR inhibitors for individualizing post transplant immunosuppression. Invited Plenary Address. 2001 A Transplant Odyssey. Istanbul, Turkey. August 23, 2001.

158. Schuman E, Glickman M, Ross J, Stokes G, Lindberg J, Sternberg WC, Money S, **Lorber MI**. Immediate use of a polyurethane graft lessens use of dialysis catheters. Annual Meeting, The American Society of Nephrology. San Francisco, CA. October 17, 2001 .
159. **Lorber MI**, GP Basadonna, AL Friedman, MJ Bia, R Formica, and JD Smith. TOR inhibition as a strategy for individualizing immunosuppression after renal transplantation. Invited Plenary Address. Immunosuppression Congress. Minneapolis, Minnesota. October 25, 2001.
160. **Lorber MI**. The role of Sirolimus and Everolimus as a possible approach for ameliorating allograft arterial injury after organ transplantation. Visiting Professor. Department of Surgery, Division of Transplantation. Duke University School of Medicine. Durham, North Carolina. October 30, 2001.
161. **Lorber MI**, Ponticelli C, Mayer HW, Schmidli H. Everolimus dose Recommendations based on efficacy modeling and simulations of therapeutic drug monitoring. American Transplant Congress. Washington DC. April 29, 2002.
162. Tedesco H, Ambuhl P, **Lorber MI**, Oyen O, Pirron U. Improved renal function following cyclosporine dose reduction in maintenance renal transplant recipients taking everolimus. American Transplant Congress. Washington DC. April 29, 2002.
163. Tai Yi, Geiselhart, L, Wang, Y, Tellides G, Schechner J, Pober JS, **Lorber MI**. Amelioration of human arterial injury in the SCID human arterial transplant model: effects of rapamycin and cyclosporine. American Transplant Congress. Washington DC. April 29, 2002.
164. **Lorber MI**, Tedesco-Silva H, Rosso Felipe C, Kahan, BD, Stolk J, Chodoff L, Sablinski T. FTY720, RAD and corticosteroids for the prevention of graft loss and acute rejection in renal allograft recipients at increased risk of delayed graft function. American Transplant Congress. Washington DC. April 29, 2002.
165. Friedman AL, Kavic S, Formica R, Bia MJ, Basadonna GP, **Lorber MI**. Increased risk of diabetes mellitus associated with morbid obesity and post transplant weight gain. American Transplant Congress. Washington DC. April 29, 2002.
166. **Lorber MI**. Transplantation, Looking Back to the Future. Presidential Address to the American Society of Transplant Surgeons. Delivered at the American Transplant Congress, Washington, D.C. April 30, 2002.
167. **Lorber MI**. Basiliximab and sirolimus to minimize calcineurin inhibitors after renal transplantation. Invited Presentation at Program on Avoidance or Minimization of Calcineurin Inhibitors. New York Academy of Medicine. New York, New York. May 29, 2002.
168. Tedesco-Silva H, **Lorber MI**, Rosso Felipe C, Kahan, BD, Stolk J, Chodoff L, Sablinski T. FTY720, RAD and corticosteroids for the prevention of graft loss and acute rejection in renal allograft recipients at increased risk of delayed graft function. Internal Congress of the Transplantation Society, Miami, Florida. August 28, 2002.

169. Tedesco H, Ambühl, Lorber, MI, Øyen, O, Pirron, O. Cyclosporine dose reduction in kidney transplant recipient taking everolimus improves renal function. Internal Congress of the Transplantation Society, Miami, Florida. August 28, 2002.
170. **Lorber MI.** Mayer HW, Schmidli H. Everolimus dose optimization using therapeutic drug monitoring: simulation results based on efficacy modeling. International Congress of the Transplantation Society, Miami, Florida. August 30, 2002.
171. **Lorber MI.** TOR inhibition as a strategy for minimizing allograft vascular injury after renal transplantation. Invited Presentation at the National Institute of Transplantation, St. Vincent's Hospital, Los Angeles CA. October 9, 2002.
172. **Lorber MI.** Strategies for ameliorating alloimmune arterial injury after organ transplantation. Visiting Professor, Transplant Grand Rounds. The University of Oregon Medical Center. Portland, Oregon. October 10, 2002.
173. **Lorber MI.** Signaling and the Major Histocompatibility Complex. Invited Plenary Session Chair. The Annual Scientific Meetings of the American Society of Histocompatibility and Immunogenetics. Nashville, TN. October 21, 2002.
174. Formica RN, Margaryan A, Friedman AL, Basadonna GP, **Lorber MI**, Bia MJ. Use of Angiotensin converting enzyme inhibitors and Angiotensin II receptor blockers are safe in the early post transplant period. Annual Meeting of the American Society of Nephrology. Philadelphia, PA. November 2, 2002.
175. **Lorber MI.** Mayer HW, Schmidli H. Therapeutic dose optimization of everolimus with TDM: Simulation results based on efficacy modeling. Annual Meeting of the American Society of Nephrology. Philadelphia, PA. November 2, 2002.
176. **Lorber MI.** Toward ameliorating alloimmune arterial injury after renal transplantation. Visiting Professor. Emory University School of Medicine. Atlanta, Georgia. December 11, 2002.